Immunicum AB (publ) Announces Approval of the International Nonproprietary Name (INN) ilixadencel for INTUVAX®
(Thomson Reuters ONE) -
Press Release
12 June 2017
Immunicum AB (publ) Announces Approval of the International Nonproprietary Name
(INN) ilixadencel for INTUVAX®
--New Designation is One of the First Cell-based Therapy Names Established by
the World Health Organization--
Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company
advancing a novel immuno-oncology treatment against a range of solid tumors,
today announced that the Company received approval of the International
Nonproprietary Name (INN), ilixadencel, for the Company's lead program
INTUVAX(®), a cancer immune primer designed to specifically reactivate the
patient's immune system to recognize and destroy tumor cells. The INN system has
been established to facilitate the identification of pharmaceutical substances
or active pharmaceutical ingredients in a unique and globally recognized manner.
Ilixadencel was the chosen nonproprietary, or "generic" name selected by the
World Health Organization (WHO) through their close collaboration with the
Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical
Preparations.
"The approval of INTUVAX' own INN, one of the first names ever established for
cell-based therapies by the WHO, is in part a recognition of the unique nature
of our product. This allows us to be consistent working with clinicians
worldwide and continuing to advance our global development program for
ilixadencel," said Carlos de Sousa, CEO of Immunicum. "We are pleased to have
had our application for the INN accepted and confirmed by the WHO. From this
point forward, we will use the nomenclature ilixadencel in all of our future
communications regarding this cell therapy."
Ilixadencel is an "off-the-shelf" allogeneic cell-based immunotherapy that is
currently being evaluated in an ongoing global Phase 2 trial known as MERECA
(MEtastatic REnal Cell CArcinoma) in kidney cancer patients. The trial is
investigating the safety and efficacy of ilixadencel and is currently underway
in eight countries in the European Union and has been cleared for initiation in
the United States by the Food and Drug Administration. It is also in Phase 1
studies to evaluate it as a potential treatment for liver cancer and
gastrointestinal stromal tumors.
About ilixadencel
Ilixadencel cell therapy product (formerly known as INTUVAX) is a cancer immune
primer, developed for the treatment of solid tumors. Its active ingredient is
activated allogeneic dendritic cells, derived from healthy blood donors.
Intratumoral injection of these cells is expected to lead to an inflammatory
response which in turn leads to tumor-specific activation of the patient's
cytotoxic T-lymphocytes.
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info(at)immunicum.com
Investor Relations Sweden
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: helena.stangberg(at)halvarsson.se
Investor and Media Relations EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or +49 175 5711562
E-mail: gschweitzer(at)macbiocom.com or smaymacbiocom.com
The Company's Certified Adviser is Redeye AB
Telephone: +46 (0) 8 545 013 31
www.redeye.se
About Immunicum AB (publ)
Immunicum is establishing a distinct immuno-oncology approach through the
development of an allogeneic off-the-shelf cell-based therapy. Our goal is to
improve survival outcomes and quality of life by priming the patient's own
immune-system to fight cancer. The company's lead product, ilixadencel, has
the potential to become a backbone component of modern cancer combination
treatments in a variety of solid tumor indications. Founded and based in
Sweden, Immunicum is publicly traded on the Nasdaq First North Premier.
www.immunicum.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 12.06.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 547340
Anzahl Zeichen: 4941
contact information:
Town:
Gothenburg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Immunicum AB (publ) Announces Approval of the International Nonproprietary Name (INN) ilixadencel for INTUVAX®"
steht unter der journalistisch-redaktionellen Verantwortung von
Immunicum AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
